ALX Oncology (NASDAQ:ALXO) outlined progress across its two clinical-stage programs—CD47 blocker evorpacept and EGFR-targeted antibody-drug conjugate (ADC) ALX2004—during a presentation at the J.P.
Learn how prebiotics, or foods with compounds that support a healthy balance of gut bacteria (microbiome), may benefit people with UC.